胃食管交界部 Barrett 食管和食管癌中 HER2 状态的荟萃分析。
HER2 status in Barrett's esophagus & esophageal cancer: a meta analysis.
机构信息
The Whiteley-Martin Research Centre, The Discipline of Surgery, The University of Sydney, Sydney Medical School, Nepean, Penrith, New South Wales, Australia.
出版信息
J Gastrointest Oncol. 2014 Feb;5(1):25-35. doi: 10.3978/j.issn.2078-6891.2013.039.
BACKGROUND
The oncogenic potential of the Human Epidermal Growth Factor Receptor 2 (HER2) is well known in the context of breast cancer however; its relationship with the development of Barrett's Esophagus (BE) and Esophageal Cancer (EC) is unclear. The aim of this meta-analysis was to determine the overall prevalence and survival of HER2+ in BE & EC.
PATIENTS AND METHODS
Several databases were searched including article reference lists. Inclusion criteria required that studies measured HER2 positivity in subjects with BE or EC.
RESULTS
33 studies were included in the meta-analysis (10 BE & 23 EC studies). The prevalence of HER2+ was found to be 24% (95% CI: 15-36%) in BE and 26% (95% CI: 19-34%) in EC. Squamous cell carcinoma (SCC) had a higher ER of 32% (95% CI: 20-48%) in comparison with adenocarcinoma (ADC) with an ER of 21% (95% CI: 14-32%). Sub group analyses showed a high geographical variance, Asia was found to be the highest prevalent area with an ER 42% (95% CI: 22-64%). The difference in survival rate between groups HER2- & HER2+ was found to be 7 months.
CONCLUSIONS
Our results highlight a high prevalence of HER2+ in subjects with adenocarcinoma. HER2+ appears to decrease the survival time of EC patients.
背景
人表皮生长因子受体 2（HER2）的致癌潜能在乳腺癌中是众所周知的；然而，其与 Barrett 食管（BE）和食管癌（EC）的发展的关系尚不清楚。本荟萃分析的目的是确定 BE 和 EC 中 HER2+的总体患病率和生存率。
患者和方法
搜索了多个数据库，包括文章参考文献列表。纳入标准要求研究测量 BE 或 EC 患者中 HER2 阳性率。
结果
荟萃分析纳入了 33 项研究（10 项 BE 研究和 23 项 EC 研究）。BE 中 HER2+的患病率为 24%（95%CI：15-36%），EC 中为 26%（95%CI：19-34%）。与腺癌（ADC）相比，鳞状细胞癌（SCC）的 ER 更高，为 32%（95%CI：20-48%），而 ADC 的 ER 为 21%（95%CI：14-32%）。亚组分析显示出高地域差异，亚洲是发病率最高的地区，患病率为 42%（95%CI：22-64%）。HER2-和 HER2+组之间的生存率差异为 7 个月。
结论
我们的结果强调了腺癌患者中 HER2+的高患病率。HER2+似乎降低了 EC 患者的生存时间。
Zotero 插件